Capital Markets Overview for Public Cannabis Companies (2017)
Summary
The passage provides aggregate financing data and market listings for cannabis‑related public companies, but it contains no specific allegations, transactions, or individuals that suggest misconduct o US cannabis firms raised $1.35 bn across 78 deals in the 12‑month period ending Sep 30 2017. Canada contributed $1.056 bn of that capital; Australia $26 m. Four cannabis firms traded on Nasdaq, one R
This document is from the House Oversight Committee Releases.
View Source CollectionTags
Related Documents (6)
Ackrell Capital Cannabis OTC Market Valuation Table (2017)
The document is a financial listing of small OTC cannabis companies with market metrics. It contains no references to influential political figures, government agencies, or alleged misconduct, offerin Provides EV multiples and stock price discounts for over 40 cannabis firms. Compiled by Ackrell Capital, a FINRA/SIPC member. Data dated November 30, 2017.
Synthetic biology and QA/QC testing market for cannabinoids
The passage is a commercial market analysis describing production methods and testing opportunities for CBD. It mentions no high‑profile officials, agencies, or controversial financial flows, and prov Synthetic biology can produce cannabinoids via fermentation. QA/QC testing standards for CBD are currently fragmented across states. Life‑science instrument makers (Agilent, Danaher, PerkinElmer, Shi
Cannabis Investment Report – Market Overview and Funding Landscape (Dec 2017)
The document is a generic industry analysis with no mention of high‑profile political figures, intelligence agencies, or controversial financial flows. It provides market commentary and fundraising to Reports $2.0 billion raised by cannabis‑related companies in 2017. Highlights Canadian exchanges (TSX, TSXV, CSE) as primary venues for cannabis listings. Notes ongoing U.S. federal prohibition limit
Cannabis Company Valuation Table from Cowen Report (Feb 2019)
The passage is a plain financial data table listing market metrics for cannabis companies. It contains no references to high‑profile individuals, government actions, or alleged misconduct, offering no Provides enterprise values, revenues, and price metrics for dozens of cannabis firms. Cites Thomson Reuters and Cowen as sources. Dated February 25, 2019, with no contextual commentary.
Ackrell Capital Cannabis Investment Report (Dec 2017) – Canadian Stock Market Comparison
The document is a routine market analysis with no mention of high‑profile individuals, government agencies, or controversial transactions. It provides generic data on exchange listings and financial c Shows that >10% of Canadian Securities Exchange listings are cannabis‑related. Compares market size and median company values across TSX, TSXV, and CSE. Outlines listing and governance requirements f
Market Overview of Publicly Traded Cannabis Companies Across U.S., Canadian, and Australian Exchanges
The passage provides aggregate financial data on cannabis‑related publicly traded firms and outlines exchange listing requirements. It contains no specific allegations, names, transactions, or links t Most cannabis companies trade on OTC in the U.S. due to lax regulations. Canadian exchanges (TSX, TSXV, CSE) have varying listing standards. CSE permits U.S. cannabis operations, unlike TSX/TSXV.
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.